Dr. Subir Basak is a pharmaceutical and biotechnology operations leader and entrepreneur with more than 30 years of experience across the US, Europe, and 40+ emerging markets in Latin America, Africa, and Asia. He is currently Senior Industry Specialist for Pharma and Biotech and Nominee Director at the International Finance Corporation (World Bank Group), and a Board Member of the Australian non-profit Pollinate.
Previously, Dr. Basak served as President and Board Member of Jubilant Life Sciences (JDDS), Board Member of Aragen, Managing Director of Vanthys (an Eli Lilly joint venture), and CEO and Board Member of Intas Biopharmaceuticals, where he led the development of 10+ biologics for EU and India commercialization and built India’s largest plasma fractionation plant. Earlier, he held strategy, business development, R&D, manufacturing, and commercial roles at Amgen and Bayer Corporation, and began his career as a Merck Research Fellow. He has also advised a UK hedge fund and a Singapore distressed asset fund.
Dr. Basak holds an M.S. and Ph.D. in Biochemical Engineering from Purdue University, where he was a Board Fellow, an MBA from the Kellogg School of Management at Northwestern University, and a B.S. in Chemical Engineering from the Indian Institute of Technology. He has completed executive education at Harvard University and The Wharton School.